Introduction {#sec1}
============

In the elderly, osteoarthritis (OA) is the most common musculoskeletal disease ([@bib32]) and will be the fourth leading cause of disability by the year 2020 ([@bib42]). The knee is particularly prone to meniscal lesions that lead to OA ([@bib8]), and a high interdependency of OA and meniscus lesions has been described ([@bib3]). In fact, meniscal injuries are the most common knee injury and account for more than 50% of the 1.5 million knee arthroscopies performed annually ([@bib7; @bib20]). The prevalence of meniscal tears increases with age ([@bib17]) and may be as high as 56% in men aged 70--90 years old ([@bib7]). Lack of robust meniscal repair in adults with or without surgical intervention has led to the development of allografts or bioengineered meniscal substitutes ([@bib11; @bib37]), and, whereas these fill the space void created following removal of the meniscus, clinical, radiological, and MRI evaluations show no protection against the development of OA ([@bib14]). The specific reasons for this lack of effect are unknown; however, a failure to successfully remodel the allograft into living tissue is one likely factor ([@bib36]). Almost all patients eventually require joint replacement ([@bib19]).

The meniscus is best described as a fibrocartilage ([@bib1]) comprising an outer, "red vascularized" part and an inner "white, unvascularized" part harboring round fibrochondrocytes ([@bib13]). Additionally, the outer surface of the meniscus is enclosed by a superficial layer with flattened, elongated fibroblast-like cells that predominantly synthesize collagen type I ([@bib23]), whereas the round fibrochondrocytes from the inner part also produce collagen type II ([@bib4]).

It has long been known that the outer, vascularized part of the meniscus is often able to successfully repair itself after injury allowing for normal meniscus function, whereas the inner meniscus produces a repair tissue in response to injury but cannot functionally regenerate. Experimental animal studies support the idea that the meniscus possesses regeneration activity. For example, fibrochondrocytes have been isolated from bovine meniscus tissue ([@bib22]) and migrating cells are found in healthy adult rabbit meniscus ([@bib41]). Regeneration of the vascular, outer part of the meniscus might be due to the presence of CD34-positive cells ([@bib25]) or to mesenchymal cells that can be released by collagenase digestion of human meniscus ([@bib33]). Because application of growth factors and fibrin clots have elicited responses by cells resident in the inner meniscus, several authors have speculated about the importance of activation of meniscal repair cells ([@bib27]). Up until today, the question remains, as to whether the inner, avascular part of the human meniscus harbors multipotent cells capable of regeneration.

Here, we describe isolation of human meniscus progenitor cells (MPCs) from the inner meniscus harvested from late-stage OA patients prior to knee replacement and show that the regenerative potential of these cells is governed by transforming growth factor β (TGF-β) signaling.

Results {#sec2}
=======

Meniscus Tissue Histology and Molecular Composition {#sec2.1}
---------------------------------------------------

By combining and modifying available classification systems for OA specimens ([@bib26; @bib43]), we developed a means to discriminate healthier human menisci from their diseased counterparts. Intact meniscus tissue is composed of a superficial zone with flattened cells that primarily synthesize collagen type I ([@bib23]). This architecture remains in healthier human menisci obtained from patients suffering from OA but is always absent in more disease samples ([Figures 1](#fig1){ref-type="fig"}A and 1B). The inner zone, containing more rounded cells that secrete collagen type I and type II, is present regardless of disease severity ([Figures 1](#fig1){ref-type="fig"}C and 1F). In diseased human menisci (score greater 4), 23% of the samples exhibit abnormal calcifications ([Figure 1](#fig1){ref-type="fig"}D) and 53% display anomalous clusters of cells ([Figure 1](#fig1){ref-type="fig"}E).

Using microarrays, we then analyzed cells obtained by culturing tissue explants from the inner zone of diseased and healthier human menisci. We focused on the top 100 most abundantly expressed genes, and among these, we identified 48 as being upregulated, i.e., exhibiting a positive fold change, and 52 as being downregulated, i.e., exhibiting a negative fold change (p value \<0.001, as listed in the figure legend). Among these top 100 genes, we found only four of the 15 arbitrarily defined potential marker genes: TIMP2, SOX9, ACAN, and MMP14, stressing the importance of these particular genes for discriminating healthier meniscal samples from diseased ones. When we analyzed eight human meniscus tissue samples, the 100 top genes clustered into two groups, healthier and diseased, as shown in the heatmap ([Figure 1](#fig1){ref-type="fig"}G). A selection is listed ([Figure 1](#fig1){ref-type="fig"}H), and the complete results can be found under GEO (accession number [GSE52042](ncbi-geo:GSE52042){#intref0010}).

To complement our microarray analyses, we performed proteomics analyses on cells grown from the healthier and diseased meniscus samples and could identify approximately 4,000 proteins as expressed by meniscal explant cells. However, only a small number of proteins produced by meniscal cells are known to be relevant for OA and meniscus pathology (as listed in [Figure 1](#fig1){ref-type="fig"}I), suggesting that for the meniscus, like other tissues studied so far, the correlation between transcriptome and proteome data is weak ([@bib12]). Upon close examination, several signaling pathway mediators stood out as being differentially expressed between cells from healthier and diseased meniscal samples. In particular, SMAD2, a mediator of the canonical TGF-β/activin signaling pathway was more abundant in healthier meniscus cells ([Figure 1](#fig1){ref-type="fig"}I; for a full listing, visit <http://www.miosge.med.uni-goettingen.de/de/?id=17>). To follow up on this finding, we performed immunohistochemical (IHC) staining and found that meniscus samples that received a high disease score exhibited a reduced IHC staining for TGF-β and SMAD2. Consistent with these findings, proteome analysis and western blotting of diseased specimens also showed a reduction in SMAD2 protein and an upregulation of RUNX2 compared to healthier specimens. These results, together with existing literature, indicated that the TGF-β/BMP pathway, with its dual osteogenic and chondrogenic actions ([@bib21]), was a good candidate to investigate in greater detail.

TGF-β/BMP Signaling in Human Osteoarthritic Meniscus Tissue {#sec2.2}
-----------------------------------------------------------

Because the deregulation of TGF-β family proteins has been described to be important for meniscus pathology ([@bib6]), we examined the TGF-β status of our samples. We observed greater staining for TGF-β3 in healthier ([Figure 2](#fig2){ref-type="fig"}A) tissue compared with diseased ([Figure 2](#fig2){ref-type="fig"}B) human menisci and also found more SMAD2/3 staining in healthier tissue ([Figure 2](#fig2){ref-type="fig"}D). Reduced staining for SMAD1 was also observed in diseased tissue ([Figure 2](#fig2){ref-type="fig"}C) compared with healthier specimens (data not shown). SMAD4 staining appeared to be similar between the two groups of human menisci ([Figure 2](#fig2){ref-type="fig"}F; data not shown). When we examined the tissues for the presence of TGF-β receptors, we did not find ALK1 expression in healthier meniscus tissues ([Figure 2](#fig2){ref-type="fig"}G) but did observe staining in blood vessels of the outer vascularized part of the same specimen, consistent with reported expression of ALK1 in endothelial cells ([Figure 2](#fig2){ref-type="fig"}H; [@bib10]). However, staining for ALK5 was positive in the healthier meniscus ([Figure 2](#fig2){ref-type="fig"}I). Some of our IHC findings were verified by western blotting using tissue extracts from the inner zone of the menisci. All blots were quantified using ImageJ64 with α-tubulin used as a control ([Figure 2](#fig2){ref-type="fig"}J). A significantly higher level of SMAD2/3 was detected in healthier than in diseased tissue extracts ([Figure 2](#fig2){ref-type="fig"}K). Interestingly, we found greater level of RUNX2 and SMAD4 in diseased specimens ([Figures 2](#fig2){ref-type="fig"}L and 2N), whereas SOX9 levels were not altered significantly ([Figure 2](#fig2){ref-type="fig"}M). Real-time RT-PCR (for primer sequences, see [Table 1](#tbl1){ref-type="table"}) revealed results consistent with western blotting for the expression of TGF-β3 ([Figure 2](#fig2){ref-type="fig"}O) and RUNX2 ([Figure 2](#fig2){ref-type="fig"}P). Expression of *SOX9* mRNA was reduced in diseased specimens ([Figure 2](#fig2){ref-type="fig"}Q), as was the expression of collagen type II ([Figure 2](#fig2){ref-type="fig"}R). Why the *SOX9* mRNA reduction is not seen on the protein level remains unclear but may be due to the half-life of the protein. The simultaneous reduction in TGF-β3 and SMAD2/3 and greater levels of RUNX2 seen in diseased meniscus have been identified as a hallmark of osteochondroprogenitor cells that are present in human tissue at late stages of OA ([@bib16; @bib34]) and suggested to us that diseased meniscus may also contain an increased number of progenitor cells.

Cells from Diseased Human Meniscus In Vitro Are Similar to the Cells Found In Vivo {#sec2.3}
----------------------------------------------------------------------------------

We used explant cultures of diseased human meniscus from late-stage OA to further examine the resident osteochondroprogenitor cell population. Because most OA cases are identified at late disease stages when the superficial zone of the meniscus has been completely lost, we concentrated on the cells from the inner, "white," avascular zone. In culture, these cells grow clonally and exhibit the spindle shape typical of mesenchymal stem cells (MSCs) ([Figure 3](#fig3){ref-type="fig"}A). Consistent with this observation, fluorescence-activated cell sorting (FACS) analysis for the stem cell markers STRO1, CD29, CD90, CD105, and CD106 showed significantly higher levels of these antigens on cells migrating out of the inner zone of diseased meniscus than in cells released after collagenase digestion of healthier specimens where the superficial zone remained intact ([Figure 3](#fig3){ref-type="fig"}B). Both populations were negative for the hematopoietic markers CD45 and CD34 (data not shown). When driven toward the chondrogenic lineage (3D alginate culture with standard chondrocyte differentiation medium) cells from damaged menisci showed 60% more SOX9 ([Figure 3](#fig3){ref-type="fig"}D), but RUNX2 was no longer detected ([Figure 3](#fig3){ref-type="fig"}E). Collagen type II appeared in chondrogenic culture conditions; however, it was undetectable in undifferentiated cells in 2D culture ([Figure 3](#fig3){ref-type="fig"}F). The levels of SOX9 ([Figure 3](#fig3){ref-type="fig"}G) and collagen type II mRNA ([Figure 3](#fig3){ref-type="fig"}H) were also significantly increased when cells were grown in 3D and chondrocyte differentiation medium. In contrast, the levels of collagen type I mRNA decreased ([Figure 3](#fig3){ref-type="fig"}I). Following osteogenic differentiation, a proportion of cells became positive for alkaline phosphatase ([Figure 3](#fig3){ref-type="fig"}J) and osteocalcin ([Figure 3](#fig3){ref-type="fig"}K), as well as alizarin red (data not shown). Oil red O-positive ([Figure 3](#fig3){ref-type="fig"}L) and PPARγ-positive (data not shown) adipocytes were identified following adipogenic differentiation.

To examine the cell migration potential ex vivo ([Figure 4](#fig4){ref-type="fig"}A), a sample of diseased meniscus tissue was placed on the scraped side of a tissue culture flask that had been 80% confluent with GFP-labeled primary meniscus cells. After 3 days, green cells were found inside the tissue sample ([Figure 4](#fig4){ref-type="fig"}B), which was confirmed by placing the sample in a new flask ([Figure 4](#fig4){ref-type="fig"}C). After an additional 7--10 days, cells, both green and unlabeled, residing in the damaged meniscus sample, were again found outside the tissue. Strikingly, cells migrated only into diseased meniscus tissues and not into the ones containing an intact superficial zone. Furthermore, a standard Boyden chamber assay revealed that the meniscus-derived cells displayed enhanced migration toward a gradient of human recombinant platelet-derived growth factor (PDGF) ([Figure 4](#fig4){ref-type="fig"}D), much like the behavior recorded for chondrogenic progenitor cells ([@bib16]). Taken together, the multilineage differentiation potential and the migration results enabled us to name the cells "meniscus progenitor cells" (MPCs).

The Influence of TGF-β3, RUNX2, and SMADs on the Chondrogenic Potential of MPCs {#sec2.4}
-------------------------------------------------------------------------------

Using real-time RT-PCR, we observed significantly higher levels of mRNA for *TGF-β3* ([Figure 5](#fig5){ref-type="fig"}A), *SMAD2* ([Figure 5](#fig5){ref-type="fig"}B), and *SMAD3* ([Figure 5](#fig5){ref-type="fig"}C) in the cells derived from healthier menisci, whereas *SOX9* was generally unchanged ([Figure 5](#fig5){ref-type="fig"}D). When examined by IHC, SMAD1 perinuclear staining ([Figure 5](#fig5){ref-type="fig"}E), SMAD2/3 ([Figure 5](#fig5){ref-type="fig"}F), and SMAD4 ([Figure 5](#fig5){ref-type="fig"}G) were all detected in cells from diseased menisci. To further elucidate the possible connection of the disease stage with the TGF-β/BMP pathways, we performed a human TGF-β/BMP signaling pathway array and found significantly higher levels of mRNA for *SMAD7* ([Figure 5](#fig5){ref-type="fig"}H), noggin ([Figure 5](#fig5){ref-type="fig"}I), and follistatin ([Figure 5](#fig5){ref-type="fig"}J) in meniscus cells from diseased tissues.

Because TGF-β enhances chondrogenesis of OA chondrocytes ([@bib40]), we treated MPCs with 10 ng/ml TGF-β3 ([Figure 6](#fig6){ref-type="fig"}A). MPCs exposed to TGF-β3 exhibited significantly greater levels of SMAD2/3 ([Figure 6](#fig6){ref-type="fig"}B) and also significantly greater levels of p-SMAD2 ([Figure 6](#fig6){ref-type="fig"}C). Treatment with TGF-β3 also increased the levels of SOX9 in the MPCs compared with controls ([Figure 6](#fig6){ref-type="fig"}D) while also decreasing RUNX2 levels significantly ([Figure 6](#fig6){ref-type="fig"}E). In contrast, MPCs treated with 10 ng/ml BMP2 (an activator of the SMAD1/5/7 axis) showed significantly reduced mRNA levels of *SMAD2* ([Figure 6](#fig6){ref-type="fig"}F) and *SOX9* ([Figure 6](#fig6){ref-type="fig"}G). When RUNX2 was knocked down in MPCs by small interfering RNA (siRNA) interference ([Figures 7](#fig7){ref-type="fig"}A and 7B), SMAD2/3 levels increased ([Figure 7](#fig7){ref-type="fig"}C); more importantly, p-SMAD2 became detectable only after the RUNX2 knockdown ([Figure 7](#fig7){ref-type="fig"}D).

Moreover, although the overexpression of SMAD1 or SMAD2 in MPCs ([Figures 7](#fig7){ref-type="fig"}E--7G) significantly increased SOX9 expression ([Figure 7](#fig7){ref-type="fig"}H), SMAD2 overexpression was more effective in reducing RUNX2 levels then SMAD1 overexpression ([Figure 7](#fig7){ref-type="fig"}I). These results demonstrate that the chondrogenic potential of MPCs is likely to be controlled by TGF-β3-mediated phosphorylation of SMAD2, which, in turn, upregulates SOX9 and downregulates RUNX2.

Discussion {#sec3}
==========

By employing a simple histopathological grading system, we have been able to separate OA tissue from patients undergoing knee replacement into samples of early OA (healthier specimens) and severe degenerative disease (diseased specimens). The discriminative power of our grading system was validated by transcriptome analysis, where the molecular pattern found in diseased samples was distinct from that found in early stage OA meniscus. Differential expression patterns have also been shown before in menisci of different age ([@bib31]). Previous results ([@bib16; @bib34]) indicated the existence of progenitor cells in cartilage tissues from late stage OA, and, in fact, when we performed explant cultures using diseased meniscus tissue, we found cells migrating out of these specimens after a few days, which was not observed for healthier menisci. The intact superficial zone, with its flattened cells positive for collagen type I ([@bib4; @bib13]) appear to be a barrier for cell migration. When removed, cells are able to migrate out of the less diseased samples. However, cell migration is more effective in diseased meniscus, indicating that inflammation and matrix degrading mediators are needed for migration. FACS analysis of these migratory meniscal cells showed that they were positive for well-known stem cell markers including STRO-1, CD105, or CD106. We also determined that these highly migratory meniscal-derived cells were multipotent; they synthesized collagen type II and suppressed RUNX2 in 3D culture when grown in chondrogenic medium and they can be differentiated into the osteoblastic and adipogenic lineage. Interestingly, a significant difference in marker expression was observed when we compared cells migrating out of diseased meniscal explants with cells derived from meniscal tissue digestions, which indicates that the migratory progenitor cells are a subpopulation of the cells found in diseased human meniscus tissue in vivo. When the protein expression characteristics of the MSC markers are considered together with their clonicity, multipotency, and migratory potential, we named these cells meniscus progenitor cells (MPCs). The cells show signs of senescence (data not shown); therefore, we prefer the term progenitor rather than stem cell.

MPCs are decidedly different from the recently described CPCs ([@bib16; @bib15]) not only due to their tissue origin and stem cell marker pattern, but also due to their ability to produce collagen type I and type II. However, they are similar as they also appear to be modulated via a balance between RUNX2 and SOX9 ([@bib24]). Despite the presence of these multipotent cells in diseased human meniscus, they are not able to contribute substantially to regeneration efforts. Although the cell clusters found might be interpreted as signs of proliferation of the progenitor cells, it is likely that the numerous mediators of inflammation and tissue degeneration present, especially, in the late stages of OA investigated here, inhibit the regenerative capacity of any stem cell present in the diseased tissue.

In articular cartilage, deletion of the type 2 TGF-β receptor results in the upregulation of RUNX2, MMP13, and ADAMTS5, which correlates with the progression of OA disease ([@bib35]), and stimulation of SMAD2/3 signaling in articular chondrocytes has been suggested as a potential therapeutic manipulation for the treatment of OA ([@bib40]). Here, we demonstrate that the treatment of MPCs with TGF-β3 results in an upregulation of SOX9 and a downregulation of RUNX2 similar to findings in articular cartilage. The shift in articular chondrocytes from SMADS2/3 to SMADS1/5 appears to be important for the development of OA, and, recently, a balancing role of endoglin (CD 105) for this shift has been highlighted ([@bib9]). This change in pathway mediators may also be the case in the diseased human meniscus, because we found lower levels of SMAD2/3 and higher levels of RUNX2 in diseased tissue compared with healthier meniscus tissue.

The complex regulatory role of the signaling balance between TGF-β/BMP in OA pathology is widely acknowledged ([@bib9; @bib39]), and our data suggest this interaction also governs meniscal cell behavior. We observe that MPCs from less diseased meniscus respond to TGF-β via the ALK5 receptor, and that this promotes chondrogenesis, whereas MPCs from more diseased meniscus are prone toward osteogenesis. Furthermore, our findings suggest that specific components of the TGF-β pathway may be suitable targets for regenerative therapies directed at diseased human meniscus in late stages of OA. As OA is a very complex disease, and multiple tissues that are integral to joint function are impacted in different ways ([@bib18]), we find it unlikely that direct TGF-β treatment of the meniscus will have significant therapeutic benefit, and undesirable side effects of TGF-β therapy have been reported, including synovial hyperplasia, inflammation, or even osteophyte formation ([@bib2; @bib38]). Our current finding supports the notion that a more nuanced understanding of the regulatory events governing MPCs biology will be necessary to identify a cell-based therapy and the modulatory factors that support using these cells for meniscal regeneration. Identification and characterization of MPCs provides direct evidence that meniscal repair cells are present in highly diseased tissue and also allows for detailed study of the signaling pathways that govern their proliferation and differentiation, a first step in identifying drug targets for the regeneration of diseased meniscus.

Experimental Procedures {#sec4}
=======================

Tissues and Preparation {#sec4.1}
-----------------------

Adult osteoarthritic lateral and medial menisci were obtained from more than 150 patients (ages 62--75 years) suffering from late-stage OA after total knee replacement operations. The patients met the American College of Rheumatology classification criteria and provided their written informed consent. Histopathological classification of OA cartilage confirmed the presence of late-stage OA ([@bib30]) of the tibial plateau and femoral condyles in all samples.

Histology and Meniscus Grading {#sec4.2}
------------------------------

For light microscopy, meniscus specimens (n = 80), including the white and red areas ([Figure 1](#fig1){ref-type="fig"}A, inset), were processed as described previously ([@bib15]), and a combined Alcian blue/nuclear fast-red staining was performed. Based on existing grading systems ([@bib26; @bib43]), we developed a simple score for meniscus degradation. The presence (1 point) or absence (2 points) of the superficial zone and the intensity of the Alcian blue staining (high = 1 point or low = 2 points) were used for evaluations. The presence of fatty degeneration and/or cell clusters (2 points) or the presence of calcifications (3 points) was also included. A minimum of 2 and a maximum score of 9 points can be reached. The threshold was set to 4 points. Three independent histologists evaluated more than 40 samples and identified 31 with a score of above 4 (diseased) and 16 with scores of below 4 (healthier). The remaining samples were not evaluated unequivocally.

Cell Isolation and Culture {#sec4.3}
--------------------------

Tissue pieces measuring 7--10 mm^3^ from the central inner zone (white area) of the healthier (n = 12) and diseased (n = 12) human menisci were excised, and care was taken not to include the outer red zone. Samples of healthier menisci with an intact superficial zone (grading score: 2, n = 12) were also excised. After 7--10 days of incubation, only samples that lacked a superficial zone showed outgrowth of cells, which were harvested, and 10^3^ cells/cm^2^ were transferred to a monolayer culture under standard conditions. 3D culturing was performed using alginate beads. Samples of 2--3 mm^3^ in size from the superficial area of healthier menisci (n = 7) and the central area of diseased menisci (n = 7) were harvested and digested with collagenase I (152 U/ml; Invitrogen), collagenase II (280 U/ml; Biochrom), and dispase (15 U/ml; Invitrogen) for 6 hr at 37°C.

Microarray Analysis and Bioinformatic Methods {#sec4.4}
---------------------------------------------

Quality control and the quantification of total RNA samples was performed, and data from ten human samples were measured using the microarray (Microarrays) ReadyArray (HS1100), which contains 48,958 probes per microarray slide from the Stanford/Illumina collaboration on the HEEBO (Human Exonic Evidence Based Oligonucleotide) set of long oligos. This chip was used in a one-color assay with a reference measurement of internal housekeeping genes. An internal QC was run and data were curated, primarily from nonzero flag values that indicate absent or poor-quality spots, resulting in 13,585 probes. Next, quantile-normalization and logarithmizing followed. We then arbitrarily selected 15 potential marker genes, TIMP1, TIMP2, TIMP3, COL3A1, RUNX2, SOX9, ACAN, PRG4, DCN, MMP9, MMP3, MMP14, ADAMTS20, ADAMTS1, and NID2 (all known to be involved in the pathogenesis of OA), to determine whether each of the ten samples belonged to the "diseased" or "healthier" group. A Pearson correlation-based hierarchical clustering approach including row scaling and Ward's minimum variance method was chosen. This analysis revealed two groups of four samples each. For the selected eight samples, a differential expression analysis including all 13,585 probes with an empirical Bayes statistic of the limma package, moderated gene-by-gene t tests and p value adjustments via the Benjamini-Hochberg method was performed.

Proteome Analysis {#sec4.5}
-----------------

In-gel digestion and peptide extraction was performed using aqueous acetonitrile, and mass spectrometric analysis was performed as described ([@bib5]). The eluent was analyzed using a Top10 method in the Data Dependent Acquisition mode on the Q Exactive high-resolution mass spectrometry system (Thermo Scientific) operated under Tune 2.2 using HCD fragmentation, with normalized collision energy of 25%. Peak lists were generated using the Raw2MSM v1.10 software (MPI for Biochemistry, Martinsried, Germany). All MS/MS samples were analyzed using Mascot (Matrix Science, v.2.4.1) set to search the NCBInr_20130805 database (selected for *Homo sapiens*, 251,430 entries). Further details, especially about normalization procedures, have already been published ([@bib5]).

Antibodies {#sec4.6}
----------

Monoclonal anti-type II collagen (CIIC1, 1:500) and anti-STRO1 (STRO1, 1:100) antibodies were obtained from the Developmental Studies Hybridoma Bank, University of Iowa. For western blotting, monoclonal α-tubulin (T6199, 1:2,000, Sigma-Aldrich), anti-SMAD2/3 (c-8, sc-133098, 1:1,000), anti-SMAD1 (A-4, sc-7965, 1:1,000), anti-SOX9 (H-90, sc-2095, 1:1,000), anti-RUNX2 (M-70, sc10758, 1:1,000), anti-SMAD4 (B-8, sc-7966, 1:1,000), anti-TGF-β3 (III, sc-83, 1:100), anti-collagen type I (C-18, sc-8784, 1:100), and anti-ALK1 (c20, sc-19547, 1:100) antibodies were from SC Biotechnology. Polyclonal anti-phospho-SMAD2 (Ser465/467, \#3101, 1:1,000) purchased from Cell Signaling Technology, and anti-ALK5 antibodies (Ab-165, E11-1126B, 1:100) from EnoGene Biotech. FACS analysis was performed with PE-coupled anti-CD29 (\#554543, 1:500), CD34 (\#345802, 1:200), CD106 (\#551146, 1:500), and fluorescein isothiocyanate (FITC)-coupled anti- CD45 (\#345808, 1:200), CD105 (\#312404, 1:500) antibodies from BD Pharmingen. Anti-CD90-PE (\#328110, 1:200) was from BioLegend. All secondary antibodies were the ones used previously ([@bib16]).

Immunohistochemistry {#sec4.7}
--------------------

Ten diseased and ten healthier samples were processed for immunohistochemistry with the HiDefDetection alkaline phosphatase mouse/rabbit system (Cell Marque). Immunoreactions were also performed with swine serum as a negative control, and figures show representatives of three different healthier and three different more diseased samples of OA patients.

Immunoblotting {#sec4.8}
--------------

Immunoblotting was performed as described previously ([@bib16]) and quantified using α-tubulin as a loading control using the ImageJ64 program.

RNA extraction and cDNA Synthesis {#sec4.9}
---------------------------------

Cells from samples of healthier and diseased menisci in P1 monolayer cultures were lysed directly in RLT buffer and subjected to RNA isolation (RNeasy Mini Kit, QIAGEN) as described ([@bib16]).

Quantitative Real-Time RT-PCR {#sec4.10}
-----------------------------

A 10 μl volume per PCR comprising 1 ng of cDNA, 5 μl of Platinum Sybr Green qPCR SuperMix (Invitrogen) and 20 pmol of each primer was chosen. The program primer 3 (<http://bioinfo.ut.ee/primer3-0.4.0/>) was used to design the primers ([Table 1](#tbl1){ref-type="table"}).

PCRs were performed as described previously, and data were normalized to a highly consistent housekeeping gene (β2M). PCR products were sequenced (Seqlab), and relative ratios were calculated ([@bib28]). Every PCR was run three times in triplicate. The intratest and intertest variations were \<1%. Primer efficiencies ranged from 1.9 to 2.1.

Cell Differentiation {#sec4.11}
--------------------

Chondrogenic differentiation was performed using 3D cell culture as described previously ([@bib16]). For osteogenic differentiation, a total of 1,000 MPCs/cm^2^ in 75 cm^2^ flasks were differentiated into cells of the osteoblastic lineage under the influence of NH OsteoDiffMedium or adipogenic differentiation was performed using NH AdipoDiffMedium (Miltenyi Biotec).

Immunofluorescence Microscopy {#sec4.12}
-----------------------------

P1 cells were grown on coverslips, fixed, and incubated with 100 μl of primary antibody (1:50 dilution in PBS) for 1 hr at room temperature. In the case of uncoupled primary antibodies, we then added secondary fluorescence-coupled antibodies (1:500 dilution in PBS) for 20 min at room temperature and stained with DAPI.

FACS Analysis {#sec4.13}
-------------

To test cells for stem cell markers, 10^6^ cells were suspended in 100 μl of PBS containing 1 μl of fluorescence-coupled antibody at room temperature for 1 hr in the dark. Anti-human-PE/FITC immunoglobulin isotype antibodies (BD Pharmingen) served as negative controls for gating. The cells were then washed twice, centrifuged, and subjected to FACS analysis using a FACScan machine (Becton Dickinson), and 10,000 living cells were analyzed ([@bib16]). For data evaluation, we used the WinMDlv2.9 program (Scripps Research Institute). The FACS Vantage SE (Becton Dickinson) was applied for cell selection and the Cell Quest Pro 2000 software package was used for analysis.

PCR Array {#sec4.14}
---------

The human TGF-β/BMP signaling pathway array was used (PAHS-035ZA_0123, SAbiosciences), according to the manufacturer's instructions, and data were normalized using the standard program of the company's online platform.

GFP Transfection {#sec4.15}
----------------

The cells (5 × 10^5^) were transfected with 2.5 μg of the pmaxGFP vector (Lonza, Koeln, Germany) in 100 μl of nucleofector solution using the Amaxa program U-23 as described before ([@bib16]).

Migration and Integration Assay {#sec4.16}
-------------------------------

In an ex vivo assay, a sample of diseased meniscus tissue was placed on the scraped side of a flask that had been 80% confluent with GFP-labeled cells. After 5--7 days, the specimens were washed with PBS, transferred to a new flask and examined using a fluorescence microscope. For the in vitro migration assay, we used a commercial two-chamber system (CytoSelect, Cell Biolabs) and extinctions were measured at 560 nm. Human recombinant PDGF (R&D Systems, 10 ng/ml) was applied as chemoattractant.

Cell Induction Experiment {#sec4.17}
-------------------------

Cells in 3D alginate were stimulated using recombinant human BMP2 (10 ng/ml, lot\# MSA3612112) and TGF-β3 (10 ng/ml, lot\# MSA3612112), both of which were obtained from R&D Systems. After 24 hr, the cells were harvested and subjected to total protein and RNA extraction.

siRNA Transfections {#sec4.18}
-------------------

The iLenti-GFP siRNA expression vector (ABM) was used for RUNX2 knockdown. The probe (CAGCACGCTATTAAATCCAAATT) that targeted Runx2 was placed under the control of H1/H6 and the GFP sequence under the CMV promoter. Control experiments were performed using a vector containing a scrambled siRNA sequence or without any vector. For the transfection of cells, see above.

Overexpression {#sec4.19}
--------------

SMAD1 and SMAD2 cloned into the pCMV5-Flag and pCMV5B-HA vectors were purchased from Addgene, Cambridge, USA and sequenced to verify the inserts. The cells were transfected either with the expression vector or the vector without the insert, as described above.

Statistical Analyses {#sec4.20}
--------------------

Statistical product and service solutions (SPSS) software version 13.0 was used. The observed data were tested statistically, and the representative data shown are the means and standard deviation of at least three different healthier and three different more diseased samples of OA patients, if not stated otherwise. After testing for normality of distribution and homogeneity of variances, we performed ANOVAs and post hoc pairwise comparisons of the mean values. The Pearson correlation coefficients were calculated to examine the relationships between parameters. A p value \< 0.05 was considered significant.
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![Characterization of Human Healthy and Diseased Meniscus Tissue\
(A) Immunohistochemistry of collagen type I in healthier meniscus (arrow); inset: low magnification of a human healthier meniscus stained for collagen type I; the black line indicates the border between the vascular part on the right side and the avascular part on the left side.\
(B) Healthier human meniscus with an intact superficial zone and flattened cells (arrow).\
(C) Diseased meniscus with a completely degenerated superficial zone where only the round cells of the inner zone remain (arrow).\
(D and E) Calcifications (D) and cell clusters (E) are signs of OA.\
(F) Immunohistochemistry of collagen type II in diseased meniscus (arrows); inset: low magnification of a human diseased meniscus stained for collagen type II. Magnification in (A)--(F), scale bar, 150 μm; inset bar, 1.7 cm.\
(G) Heatmap of the top 100 differentially expressed genes with p values \< 0.001. The red color indicates upregulated genes, and the blue color indicates downregulated genes. The upregulated genes in diseased meniscus compared with healthier tissue are ACTR2, KRT, HSPD1, CALU, HSPA9, BAX, CCDC80, C17orf59, HSP90AB1, CDC42, HNRNPH1, FKBP9, MT1DP, G3BP1, CTTN, COL6A1, TAF15, ELAVL1, MCL1, AL, HSPA4, CXorf40A CXorf40B, TCP1, RP5, VHL, PRPF4, BAG5, RIOK3, FCF1, SPTLC1, APH1A, RNF170, RCN3, DENR, CAPZB, MBNL1, CASC4, ASB1, MRPS10, RAB23, PAAF1, FARSB, NASP, NUDC, ZNF346, RIOK1, and GAR1. The downregulated genes in diseased meniscus compared with healthier tissue are RNF103, SLC41A3, SNX19, GTFIP1, ERF, NBPF10 NBPF3, OSBPL10, ADAM15, KIAA0930, ZMAT3, AL845464.3, ANTXR1, ENDOD1, ZNFX1, GLT8D2, RP5-1022P6.4, ENG, POMZP3, C11orf95, LPCAT1, EPN2, POMZP3, RAB11FIP3, TBC1D2B, PCDHGC3, MMP14, TRPM4, HDAC5, ABL1, SOX9, Antxr1, BCAN, ZP3, ABR, SNX33, RPS6KA4, CXCR7, NCOR2, PLEC, GPC1, SEMA3C, PDGFRB, LUM, ACAN, CSPG4, OAS1, TIMP2, VCAM1, LAM5, PRSS54, PCDHB1, and FMOD.\
(H) Selected microarray data of genes that are known from the literature to be highly expressed in healthy hyaline cartilage tissue (SOX9, PDFGFRB, ACAN, TIMP2, and FMOD). These genes were significantly downregulated in cells derived from diseased tissue compared with cells from healthier meniscus tissue. Only COL6, as indicator gene of an active pericellular matrix of chondrocytes ([@bib29]), is upregulated.\
(I) Peptide abundance of selected genes shown as the mean of four experiments that analyzed cells that migrated out from meniscus from healthier and diseased samples in vitro (SD).](gr1){#fig1}

![The TGF-β Pathway Players in Healthy and Diseased Meniscus Tissue\
(A and B) Healthier meniscus stained for TGF-β3 (A) compared with the sparse staining in diseased meniscus (B).\
(C--E) Sparse staining of SMAD1 in diseased meniscus tissue (C). SMAD2/3 in healthier (D) compared to diseased meniscus tissue (E).\
(F--H) SMAD4 staining in healthier meniscus tissue (F). No ALK1 staining was detectable in healthier meniscus tissue (G), whereas blood vessels from the outer, vascularized part of the same specimen served as positive control (H).\
(I) However, ALK5 was detected in healthier meniscus tissue. Magnification in (A)--(I); scale bar, 150 μm.\
(J--N) Western blotting and quantification using ImageJ64: (J) α-tubulin shows equal loading; the first lanes of the blots corresponding to the dark gray bars in the graphs always show the healthier specimens. The diseased specimens are always found in the second lanes of the blots, which correspond to the light gray bars in the graphs. A significantly greater level of SMAD2/3 in healthier meniscus tissues is found (K). RUNX2 is almost undetectable in healthier tissue, whereas it is significantly elevated in diseased meniscus (L). SOX9 showed no significant differences between tissue types (M). SMAD4 was increased significantly in diseased meniscus (N).\
(O--R) Quantitative real-time RT-PCR results: (O) *TGF-β3* mRNA is significantly increased in healthier meniscus tissue; however, *RUNX2* mRNA levels are significantly reduced in healthier meniscus (P). (Q and R) (Q) *SOX9* mRNA is significantly reduced in diseased meniscus, which is in line with the significant reduction in collagen type II mRNA (R).\
^∗^Significant differences (p ≤ 0.05); error bars denote the means ± SD of three different healthier and three different diseased samples of OA patients for mRNA and western blotting experiments.](gr2){#fig2}

![Characterization of Cells from the Diseased Meniscus Tissue as MPCs\
(A) Explant cell culture of cells migrating out of a diseased meniscus specimen. Magnification in (A), scale bar, 150 μm.\
(B) FACS data showed that migratory cells from diseased meniscus explant cultures obtained without collagenase digestion expressed significantly more stem cell markers, including STRO1, CD29, CD105, CD106 (bars on left side), than cells obtained via collagenase digestion from a healthier meniscus (bars on right side). CD90 was expressed equally in the two cell populations.\
(C) α-tubulin loading control; the first lanes always represent the 2D control experiments, the second lanes always represent the 3D differentiation, and the third lanes always represent the 3D differentiation together with the chondrogenic differentiation medium (3D + chon. diff.).\
(D) Production of SOX9 is significantly increased compared with the control in 2D and 3D cultures.\
(E) RUNX2 was undetectable following 3D + chon. diff. culture.\
(F) Collagen type II was present after 3D culture and 3D + chon. diff. culturing.\
(G and H) Western blotting data were corroborated by mRNA results that revealed significantly higher levels of *SOX9* mRNA (G) and collagen type II (H) following 3D + chon. diff. culture compared with control cells in 2D culture.\
(I) Collagen type I mRNA decreased significantly following 3D + chon. diff. culture.\
(J--L) After osteogenic differentiation, cells become positive for alkaline phosphatase (J) and (K) osteocalcin. Adipogenic differentiation is indicated by positive oil red O staining (L). Scale bars, 150 μm in (J)--(L).\
^∗^Significant differences (p ≤ 0.05); error bars denote the means ± SD of three individual experiments.](gr3){#fig3}

![Migration Potential of MPCs\
(A, top flasks) MPCs were GFP labeled, enriched via FACS to 97%, and cultured. (Middle flasks) Upon reaching 80% confluence, one side was scraped, and a sample of diseased meniscus tissue was placed on the cell-free side. After 3--4 days, MPCs repopulated and migrated into the tissue sample. (Bottom flasks) The tissues were washed with 1 × PBS solution and transferred into a new flask, and, after 7--10 days, some labeled and unlabeled MPCs migrated out again.\
(B) The labeled cells adjacent to the diseased meniscus tissue.\
(C) Labeled MPCs in the sample of the diseased tissue after washing and transferal to a new flask. Scale bar, 150 μm in (C) and (D).\
(D) Boyden chamber assay results showing that significantly more MPCs were attracted by human recombinant PDGF compared with controls.\
^∗^Significant differences (p ≤ 0.05); error bars denote the means ± SD of three individual experiments.](gr4){#fig4}

![TGF-β Pathway Players in MPCs\
(A--C) *TGF*-*β3* mRNA levels are significantly higher in cells from healthier samples (A), which is consistent with *SMAD2* (B) and *SMAD3* (C) mRNA.\
(D) No significant difference was observed for *SOX9* mRNA; however, a tendency toward higher levels in cells derived from healthier tissue was noted.\
(E--G) Immunocytochemistry of inner diseased meniscal cells positive for SMAD1 (E); note the punctuate perinuclear pattern, SMAD2/3 (F), and SMAD4 (G).\
(H--J) The human PCR array for the TGF-β/BMP pathway revealed high levels of mRNA of inhibitors of the TGF-β/BMP axis, for example, *SMAD7* (H) noggin (I), follistatin (J), in cells obtained from inner diseased meniscus.\
^∗^Significant differences (p ≤ 0.05); error bars denote the means ± SD of three different healthier and three different diseased samples of OA patients. Scale bar, 150 μm in (E)--(G).](gr5){#fig5}

![The Effect of TGF-β on MPCs\
(A) α-Tubulin indicates equal loading of the gel lanes; also in this figure, the first lanes in the blots and the dark gray bars in the graphs represent control experiments, whereas the second lanes and the light gray bars represent the TGF-β3 stimulation experiments.\
(B and C) Following stimulation of MPCs with 10 ng/ml TGF-β3 for 24 hr, total SMAD2/3 (B) was significantly increased and active p-SMAD2 was significantly upregulated (C).\
(D and E) In turn, SOX9 increased significantly (D) and RUNX2 was reduced significantly (E).\
(F and G) In contrast, following stimulation of MPCs with 10 ng/ml BMP2 for 24 hr, total *SMAD2* was reduced significantly (F), as well as *SOX9* (G), shown by real-time RT-PCR.\
^∗^Significant differences (p ≤ 0.05); error bars denote the means ± SD of three individual experiments.](gr6){#fig6}

![Knockdown of RUNX2 and Overexpression of SMADs\
(A) α-tubulin was used for the quantification with ImageJ64; the first lanes of the blots always represent the controls as do the gray bars in the graphs, whereas the second lanes of the blots and the light gray bars of the graphs always represent the RUNX2 KD.\
(B) Following RUNX2 KD, the protein was undetectable (lane 2) compared with the control (lane 1).\
(C--E) In turn, total SMAD2/3 increased significantly (C) and enabled the detection of p-SMAD2 (D). Overexpression (OE) of SMAD1 and SMAD2. (E) α-tubulin was applied for quantification, the first lanes of the blots always represent the controls as do the dark gray bars in the graphs. The second lanes and the light gray bars represent SMAD1 OE. Finally, the third lanes of the blots and the black bars of the graphs represent the OE of SMAD2.\
(F) SMAD1 OE is seen in lane 2.\
(G) SMAD2 OE is seen in lane 3.\
(H) OE of SMAD1 and SMAD2 results in a significant upregulation of SOX9.\
(I) OE of SMAD2 results in a greater reduction of RUNX2 as does OE of SMAD1.\
^∗^Significant differences (p ≤ 0.05); error bars denote the means ± SD of three individual experiments.](gr7){#fig7}

###### 

Primer Sequences

  GeneID       Forward Primer                    Reverse Primer                     Accession Number
  ------------ --------------------------------- ---------------------------------- ------------------
  *SMAD1*      5′-TCTTCAGAGCCACCATGAACTAA-3′     5′-AACCAGCACAGGAGGAAGTACAG-3′      NM_005900
  *SMAD2*      5′-GTCTCTTGATGGTCGTCTCCA-3′       5′-TTCTGTTAGGATCTCGGTGTGTC-3′      NG_029946
  *SMAD3*      5′-CCATCCTGCCTTTCACTC-3′          5′-TGGTGATGCACTTGGTGT-3′           AB004922
  *SMAD4*      5′-GCACAAGGTTGGTTGCTAAGA-3′       5′-GCAGAACAGTGAGACATTAGGTAGAG-3′   NG_013013
  *TGF*-*β3*   5′-CTTTGGACACCAATTACTGCTTC-3′     5′-GGGTTCAGAGTGTTGTACAGTCC-3′      NM_003239.2
  *RUNX2*      5′-TTCCAGACCAGCAGCACTC-3′         5′-CAGCGTCAACACCATCATT-3′          NM_004348
  *COL1A1*     5′-TTCCCCCAGCCACAAAGAGTC-3′       5′-CGTCATCGCACAACACCT-3′           NM_000088
  *COL2A1*     5′-CTCCTGGAGCATCTGGAGAC-3′        5′-ACCACGATCACCCTTGACTC-3′         NM_033150
  *SOX9*       5′-CAGGCTTTGCGATTTAAGGA-3′        5′-CCGTTTTAAGGCTCAAGGTG-3′         Z46629
  *β2M*        5′-TGCTGTCTCCATGTTTGATGTATCT-3′   5′-TCTCTGCTCCCCACCTCTAA-3′         NM_004048

[^1]: Co-first author
